• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中性粒细胞激活和中性粒细胞胞外诱捕网(NETs)在 COVID-19 急性呼吸窘迫综合征和免疫血栓形成中的作用。

Neutrophil activation and neutrophil extracellular traps (NETs) in COVID-19 ARDS and immunothrombosis.

机构信息

Dompé farmaceutici SpA, L'Aquila, Italy.

Dompé farmaceutici SpA, Napoli, Italy.

出版信息

Eur J Immunol. 2023 Jan;53(1):e2250010. doi: 10.1002/eji.202250010. Epub 2022 Nov 1.

DOI:10.1002/eji.202250010
PMID:36239164
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9874644/
Abstract

Acute respiratory distress syndrome (ARDS) is an acute inflammatory condition with a dramatic increase in incidence since the beginning of the coronavirus disease 19 (COVID-19) pandemic. Neutrophils play a vital role in the immunopathology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by triggering the formation of neutrophil extracellular traps (NETs), producing cytokines including interleukin-8 (CXCL8), and mediating the recruitment of other immune cells to regulate processes such as acute and chronic inflammation, which can lead to ARDS. CXCL8 is involved in the recruitment, activation, and degranulation of neutrophils, and therefore contributes to inflammation amplification and severity of disease. Furthermore, activation of neutrophils also supports a prothrombotic phenotype, which may explain the development of immunothrombosis observed in COVID-19 ARDS. This review aims to describe hyperinflammatory ARDS due to SARS-CoV-2 infection. In addition, we address the critical role of polymorphonuclear neutrophils, inflammatory cytokines, and the potential targeting of CXCL8 in treating the hyperinflammatory ARDS population.

摘要

急性呼吸窘迫综合征(ARDS)是一种急性炎症性疾病,自 2019 年冠状病毒病(COVID-19)大流行开始以来,其发病率显著上升。中性粒细胞通过触发中性粒细胞胞外诱捕网(NETs)的形成、产生包括白细胞介素-8(CXCL8)在内的细胞因子,并介导其他免疫细胞的募集,在严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染的免疫病理学中发挥重要作用,从而调节急性和慢性炎症等过程,导致 ARDS。CXCL8 参与中性粒细胞的募集、激活和脱颗粒,因此有助于炎症放大和疾病的严重程度。此外,中性粒细胞的激活还支持促血栓形成表型,这可能解释了 COVID-19 ARDS 中观察到的免疫性血栓形成的发展。本综述旨在描述 SARS-CoV-2 感染引起的过度炎症性 ARDS。此外,我们还探讨了多形核中性粒细胞、炎症细胞因子的关键作用,以及靶向 CXCL8 在治疗过度炎症性 ARDS 人群中的潜在作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9253/9874644/a76887d53d6c/EJI-53-0-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9253/9874644/73ef8734bfb6/EJI-53-0-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9253/9874644/61f64ba90a4b/EJI-53-0-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9253/9874644/a76887d53d6c/EJI-53-0-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9253/9874644/73ef8734bfb6/EJI-53-0-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9253/9874644/61f64ba90a4b/EJI-53-0-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9253/9874644/a76887d53d6c/EJI-53-0-g002.jpg

相似文献

1
Neutrophil activation and neutrophil extracellular traps (NETs) in COVID-19 ARDS and immunothrombosis.中性粒细胞激活和中性粒细胞胞外诱捕网(NETs)在 COVID-19 急性呼吸窘迫综合征和免疫血栓形成中的作用。
Eur J Immunol. 2023 Jan;53(1):e2250010. doi: 10.1002/eji.202250010. Epub 2022 Nov 1.
2
NETosis and Neutrophil Extracellular Traps in COVID-19: Immunothrombosis and Beyond.NETosis 和 COVID-19 中的中性粒细胞胞外陷阱:免疫血栓形成及其他。
Front Immunol. 2022 Mar 2;13:838011. doi: 10.3389/fimmu.2022.838011. eCollection 2022.
3
COVID-19: Lung-Centric Immunothrombosis.COVID-19:以肺为中心的免疫血栓形成。
Front Cell Infect Microbiol. 2021 Jun 11;11:679878. doi: 10.3389/fcimb.2021.679878. eCollection 2021.
4
Neutrophils in COVID-19: recent insights and advances.新型冠状病毒肺炎中的中性粒细胞:最新的认识和进展。
Virol J. 2023 Aug 2;20(1):169. doi: 10.1186/s12985-023-02116-w.
5
Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome.中性粒细胞胞外诱捕网在新冠病毒疾病急性呼吸窘迫综合征的免疫性血栓形成中发挥作用。
Blood. 2020 Sep 3;136(10):1169-1179. doi: 10.1182/blood.2020007008.
6
A functionally distinct neutrophil landscape in severe COVID-19 reveals opportunities for adjunctive therapies.在严重 COVID-19 中,功能独特的中性粒细胞图谱揭示了辅助治疗的机会。
JCI Insight. 2022 Jan 25;7(2):e152291. doi: 10.1172/jci.insight.152291.
7
CLEC5A and TLR2 are critical in SARS-CoV-2-induced NET formation and lung inflammation.CLEC5A 和 TLR2 在 SARS-CoV-2 诱导的 NET 形成和肺部炎症中起关键作用。
J Biomed Sci. 2022 Jul 11;29(1):52. doi: 10.1186/s12929-022-00832-z.
8
Pathomechanisms Underlying Hypoxemia in Two COVID-19-Associated Acute Respiratory Distress Syndrome Phenotypes: Insights From Thrombosis and Hemostasis.两种 COVID-19 相关急性呼吸窘迫综合征表型低氧血症的发病机制:血栓形成和止血的见解。
Shock. 2022 Jan 1;57(1):1-6. doi: 10.1097/SHK.0000000000001825.
9
Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality.中性粒细胞胞外陷阱 (NETs) 与新冠病毒 2019 (Covid-19):治疗模式的新前沿。
Int Immunopharmacol. 2022 Mar;104:108516. doi: 10.1016/j.intimp.2021.108516. Epub 2022 Jan 6.
10
Self-sustaining IL-8 loops drive a prothrombotic neutrophil phenotype in severe COVID-19.自维持的 IL-8 循环导致严重 COVID-19 中的促血栓形成中性粒细胞表型。
JCI Insight. 2021 Sep 22;6(18):e150862. doi: 10.1172/jci.insight.150862.

引用本文的文献

1
COVID-19: a vascular nightmare unfolding.新冠病毒肺炎:一场正在展现的血管噩梦。
Front Immunol. 2025 Aug 1;16:1593885. doi: 10.3389/fimmu.2025.1593885. eCollection 2025.
2
Epigenetic Regulation of Neutrophils in ARDS.急性呼吸窘迫综合征中中性粒细胞的表观遗传调控
Cells. 2025 Jul 25;14(15):1151. doi: 10.3390/cells14151151.
3
Advanced nanotherapies for precision treatment of inflammatory lung diseases.用于炎症性肺病精准治疗的先进纳米疗法。

本文引用的文献

1
Identification of bronchoalveolar and blood immune-inflammatory biomarker signature associated with poor 28-day outcome in critically ill COVID-19 patients.鉴定与危重症 COVID-19 患者 28 天预后不良相关的支气管肺泡和血液免疫炎症生物标志物特征。
Sci Rep. 2022 Jun 9;12(1):9502. doi: 10.1038/s41598-022-13179-0.
2
A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia.一项关于瑞帕霉素治疗COVID-19肺炎住院患者疗效和安全性的多中心2期随机对照研究。 (注:原文中药物名称可能有误,根据语境推测应该是“Remdesivir”(瑞德西韦),而不是“Reparixin”,翻译已按照推测修正,如原文无误,请忽略此注释)
Infect Dis Ther. 2022 Aug;11(4):1559-1574. doi: 10.1007/s40121-022-00644-6. Epub 2022 May 26.
3
Bioact Mater. 2025 Jul 20;53:329-365. doi: 10.1016/j.bioactmat.2025.07.028. eCollection 2025 Nov.
4
Dipeptidyl peptidase-1 inhibitors in bronchiectasis.支气管扩张症中的二肽基肽酶-1抑制剂
Eur Respir Rev. 2025 Jun 18;34(176). doi: 10.1183/16000617.0257-2024. Print 2025 Apr.
5
Comparative analysis of neutrophil dynamics and disease in SARS-CoV-2 Delta and Omicron variants utilizing an feline model for COVID-19.利用猫科动物COVID-19模型对SARS-CoV-2 Delta和Omicron变体中的中性粒细胞动态和疾病进行比较分析。
Front Immunol. 2025 May 22;16:1547918. doi: 10.3389/fimmu.2025.1547918. eCollection 2025.
6
A Web of Challenges: The Therapeutic Struggle to Target NETs in Disease.挑战之网:针对疾病中神经内分泌肿瘤的治疗难题
Int J Mol Sci. 2025 May 16;26(10):4773. doi: 10.3390/ijms26104773.
7
Baicalin Modulates Glycolysis the PKC/Raf/MEK/ERK and PI3K/AKT Signaling Pathways to Attenuate IFN-I-Induced Neutrophil NETosis.黄芩苷通过调节糖酵解、PKC/Raf/MEK/ERK和PI3K/AKT信号通路减轻I型干扰素诱导的中性粒细胞胞外陷阱形成。
Mediators Inflamm. 2025 May 19;2025:8822728. doi: 10.1155/mi/8822728. eCollection 2025.
8
Age influences blood cell-based immune deregulation antibody response and unfavorable clinical outcomes in COVID-19 patients.年龄影响新冠病毒疾病(COVID-19)患者基于血细胞的免疫失调、抗体反应及不良临床结局。
Sci Rep. 2025 May 20;15(1):17431. doi: 10.1038/s41598-025-95722-3.
9
HLA Polymorphisms and COVID-19 Susceptibility and Severity: Insights From an Iranian Patients Cohort.HLA多态性与COVID-19易感性及严重程度:来自伊朗患者队列的见解
J Cell Mol Med. 2025 May;29(9):e70570. doi: 10.1111/jcmm.70570.
10
A machine learning model for predicting acute respiratory distress syndrome risk in patients with sepsis using circulating immune cell parameters: a retrospective study.一项使用循环免疫细胞参数预测脓毒症患者急性呼吸窘迫综合征风险的机器学习模型:一项回顾性研究。
BMC Infect Dis. 2025 Apr 21;25(1):568. doi: 10.1186/s12879-025-10974-8.
NETosis and Neutrophil Extracellular Traps in COVID-19: Immunothrombosis and Beyond.NETosis 和 COVID-19 中的中性粒细胞胞外陷阱:免疫血栓形成及其他。
Front Immunol. 2022 Mar 2;13:838011. doi: 10.3389/fimmu.2022.838011. eCollection 2022.
4
PAD Inhibitors as a Potential Treatment for SARS-CoV-2 Immunothrombosis.外周动脉疾病抑制剂作为治疗新型冠状病毒免疫性血栓形成的潜在疗法。
Biomedicines. 2021 Dec 9;9(12):1867. doi: 10.3390/biomedicines9121867.
5
A functionally distinct neutrophil landscape in severe COVID-19 reveals opportunities for adjunctive therapies.在严重 COVID-19 中,功能独特的中性粒细胞图谱揭示了辅助治疗的机会。
JCI Insight. 2022 Jan 25;7(2):e152291. doi: 10.1172/jci.insight.152291.
6
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial.伦齐单抗治疗 COVID-19 肺炎住院患者(LIVE-AIR):一项 3 期、随机、安慰剂对照试验。
Lancet Respir Med. 2022 Mar;10(3):237-246. doi: 10.1016/S2213-2600(21)00494-X. Epub 2021 Dec 1.
7
Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.抗白细胞介素药物治疗 COVID-19 患者伴细胞因子释放综合征(COV-AID)的效果:一项析因、随机、对照试验。
Lancet Respir Med. 2021 Dec;9(12):1427-1438. doi: 10.1016/S2213-2600(21)00377-5. Epub 2021 Oct 29.
8
Non-Randomized Trial of Dornase Alfa for Acute Respiratory Distress Syndrome Secondary to Covid-19.COVID-19 继发急性呼吸窘迫综合征患者使用脱氧核糖核酸酶治疗的非随机临床试验。
Front Immunol. 2021 Oct 20;12:714833. doi: 10.3389/fimmu.2021.714833. eCollection 2021.
9
Characteristics and Outcomes of US Patients Hospitalized With COVID-19.美国 COVID-19 住院患者的特征和结局。
Am J Crit Care. 2022 Mar 1;31(2):146-157. doi: 10.4037/ajcc2022549.
10
The Epidemiology of Acute Respiratory Distress Syndrome Before and After Coronavirus Disease 2019.2019冠状病毒病前后急性呼吸窘迫综合征的流行病学
Crit Care Clin. 2021 Oct;37(4):703-716. doi: 10.1016/j.ccc.2021.05.001.